SCHEMBL3272341

SCHEMBL3272341

O=P(O)(O)CCCC(N1CCNCCNCCNCC1)P(=O)(O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
GRIN2D O15399 2/20 0.36
GRIN3B O60391 2/20 0.36
THRB P10828 2/20 0.36
GRIN1 Q05586 2/20 0.36
GRIN2A Q12879 2/20 0.36
GRIN2B Q13224 2/20 0.36
GRIN2C Q14957 2/20 0.36
GRIN3A Q8TCU5 2/20 0.36
LMNA P02545 2/20 0.36
CYP1A2 P05177 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
RECQL P46063 1/20 0.36
ENPEP Q07075 1/20 0.36
TYMS P04818 1/20 0.35
ANPEP P15144 1/20 0.34
ERAP2 Q6P179 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9356820 0.90 ANPEP (0.36) GRIN2DGRIN3BTHRBGRIN1GRIN2A
SCHEMBL7816405 0.86 ALDH1A1 (0.45) ALDH1A1TDP1GRIN2DGRIN3BTHRB
Ammonia Solution, Strong SCHEMBL786750 0.84 ALDH1A1 (0.44) ALDH1A1TDP1GRIN2DGRIN3BTHRB
Ammonia Solution, Strong SCHEMBL8010381 0.79 FDPS (0.47) ALDH1A1TDP1GRIN2DGRIN3BTHRB
SCHEMBL4736414 0.77 ANPEP (0.38) ANPEPERAP2
Ammonia Solution, Strong SCHEMBL11336508 0.76 FDPS (0.42) ALDH1A1TDP1GRIN2DGRIN3BTHRB
SCHEMBL10448870 0.73 TYMS (0.58) ALDH1A1TDP1GRIN2DGRIN3BTHRB
SCHEMBL3277730 0.70 FDPS (0.58) ANPEPERAP2SIGMAR1
SCHEMBL9175624 0.70 FDPS (0.58) ANPEPERAP2SIGMAR1
SCHEMBL4447243 0.70 FOLH1 (0.39) GRIN2DGRIN3BTHRBGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7097823-B2 High dose radionuclide complexes for bone marrow suppression NEORX CORPORATION (US) 2006-08-29 US claimed
US-20050238578-A1 High dose radionuclide complexes for bone marrow suppression NEORX CORPORATION 2005-10-27 US claimed
US-20050063905-A1 High dose radionuclide complexes for bone marrow suppression NEORX CORPORATION 2005-03-24 US claimed
US-6767531-B2 RADIONUCLIDE COMPLEXED WITH A CHELATING AGENT SUCH AS MACROCYCLIC AMINOPHOSPHONIC ACID NEORX CORPORATION 2004-07-27 US claimed
US-20030118508-A1 Treatment of osteomyelitis with radiopharmaceuticals DOW GLOBAL TECHNOLOGIES INC. 2003-06-26 US claimed
US-20020176818-A1 High dose radionuclide complexes for bone marrow suppression PONIARD PHARMACEUTICALS, INC. 2002-11-28 US claimed
EP-1191948-A2 HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION NEORX CORPORATION (US) 2002-04-03 EP claimed
WO-2000076556-A9 HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION NEORX CORP (US) 2001-11-08 WO claimed
WO-2000076556-A2 HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION NEORX CORPORATION (US) 2000-12-21 WO claimed
EP-0462787-A1 Radiopharmaceutical formulations, their method of administration and process of preparation THE DOW CHEMICAL COMPANY (US) 1991-12-27 EP claimed
US-5059412-A Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors THE DOW CHEMICAL COMPANY (US) 1991-10-22 US claimed
US-4976950-A ADMINISTERING COMPLEX OF YTTRIUM-90 AND 1,4,7,10-TETRAAZACYCLO DODECANE AMINOPHOSPHONIC ACID THE DOW CHEMICAL COMPANY (US) 1990-12-11 US claimed
EP-0374501-A1 Bone marrow suppressing agents THE DOW CHEMICAL COMPANY (US) 1990-06-27 EP claimed
US-4882142-A ANTITUMOR THE DOW CHEMICAL COMPANY (US) 1989-11-21 US claimed
EP-4351652-A1 DENDRIMER CONJUGATES AND METHODS OF USE THEREOF Ashvattha Therapeutics, Inc. (US) 2024-04-17 EP disclosed
US-20230398241-A1 RADIOLABELED ETHER DENDRIMER CONJUGATES FOR PET IMAGING AND RADIOTHERAPY Ashvattha Therapeutics, Inc. (US) 2023-12-14 US disclosed
US-20230364244-A1 DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY Ashvattha Therapeutics, Inc. (US) 2023-11-16 US disclosed
US-4976950-A ADMINISTERING COMPLEX OF YTTRIUM-90 AND 1,4,7,10-TETRAAZACYCLO DODECANE AMINOPHOSPHONIC ACID THE DOW CHEMICAL COMPANY (US) 1990-12-11 US disclosed
US-4882142-A ANTITUMOR THE DOW CHEMICAL COMPANY (US) 1989-11-21 US disclosed
US-4882142-A ANTITUMOR THE DOW CHEMICAL COMPANY (US) 1989-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230398241-A1 RADIOLABELED ETHER DENDRIMER CONJUGATES FOR PET IMAGING AND RADIOTHERAPY ESRRG, CD47, CD68 ALDH1A1 3122/4885TDP1 1572/4885GRIN2D 851/4885
US-20050238578-A1 High dose radionuclide complexes for bone marrow suppression CSF3R, ACP1, BPGM ALDH1A1 4382/4885TDP1 3096/4885GRIN2D 4748/4885
US-20020176818-A1 High dose radionuclide complexes for bone marrow suppression CSF3R, ACP1, BPGM ALDH1A1 4382/4885TDP1 3096/4885GRIN2D 4748/4885
US-20050063905-A1 High dose radionuclide complexes for bone marrow suppression CSF3R, ACP1, BPGM ALDH1A1 4382/4885TDP1 3096/4885GRIN2D 4748/4885
US-20230364244-A1 DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY PPARA, PPARD, PPARG ALDH1A1 719/4885TDP1 4024/4885GRIN2D 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.